Lakefront Biotherapeutics American Depositary Shares
LKFT
92 hedge funds and large institutions have $1.06B invested in Lakefront Biotherapeutics American Depositary Shares in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 10 closing their positions.
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
52% more capital invested
Capital invested by funds: $698M → $1.06B (+$360M)
17% more call options, than puts
Call options by funds: $6.89M | Put options by funds: $5.88M
16% more funds holding
Funds holding: 79 → 92 (+13)
2.72% more ownership
Funds ownership: 11.55% → 14.28% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$122M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$26.7M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$18.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$14.4M |
| 5 |
Jane Street
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$13.9M |
| 2 |
O
OrbiMed
New York
|
-$10.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.51M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.93M |
| 5 |
Renaissance Technologies
New York
|
-$5.57M |
LKFT Hedge Fund Activity: Q3 2018 in Review
92 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2018, worth a combined $1.06B — up 52% from $698M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LKFT positions and 10 closed out — a net gain of 13 holders — while 29 added to existing stakes and 29 trimmed.
The largest buyer was Sands Capital Management, adding an estimated $122M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $13.9M sold.
- 92 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2018, up from 79 in Q2 2018.
- Funds reported $1.06B of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2018, up 52% quarter-over-quarter.
- 23 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2018 and 10 closed out, a net change of +13 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2018 was Sands Capital Management, an estimated $122M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2018 was Perceptive Advisors, an estimated $13.9M sold.
Based on aggregated 13F filings for Q3 2018.